Prognostic value of PD-L1 expression in patients with unresectable stage III non-small cell lung cancer treated with chemoradiotherapy

Table 1 Clinical characteristic of patients regarding PD-L1 expression

Characteristics	All, n	PD-L1 ≥ 1%, n	(%)	PD-L1 negative, n	(%)	p
All patients	117	80	68.4	37	31.6
Age (years)						0.106
Median	61	62		60
Range	47–77	47–77		50–69
Gender						0.392
Female	38	28	35	10	27
Male	79	52	65	27	73
Histology						0.820
Squamous ca	71	47	58.8	24	64.9
Adenoca	39	28	35	11	29.7
Other	7	5	6.2	2	5.4
Smoking status						0.829
Current	67	44	56.4	23	62.2
Former	44	31	39.8	13	35.1
Never	4	3	3.8	1	2.7
Stage						0.079
IIIA	30	25	31.3	5	13.5
IIIB	75	46	57.5	29	78.4
IIIC	12	9	11.3	3	8.1
ECOG PS						0.806
0	58	39	48.7	19	51.4
1	57	40	50	17	45.9
2	2	1	1.3	1	2.7
RT dose (Gy)						0.793
Median		60		60
Range		54–66		55–66
ChT (number of cycles)						0.406
Median		3		3
Range		1–5		1–5
CRP after ChT/RT						0.242
≤ 2 × ULN	74	53	67.9	21	56.8
> 2 × ULN	41	25	32.1	16	43.2

ChT chemotherapy, ECOG PS Eastern Cooperative Oncology Group performance status, n number, RT radiotherapy, CRP C-reactive protein, ULN upper limit of normal

ISSN: 1748-717X